Table 3.
TNBC subtype | Current proposed therapy | Proposed siRNA nanoparticle strategy |
---|---|---|
Basal-like | Cisplatin | siBRCA + cisplatin |
Mesenchymal | PI3K/mTOR inhibitor | sip110β + MEK inhibitor siPIK3CA mutant + chemo siGF combination siEMT combination |
Luminal androgen receptor | Bicalutamide | siAR |
GF – growth factor; EMT – Epithelial-mesenchymal transition; AR – Androgen receptor